Patients
gastric/colorectal cancer, cancer, hypersensitivity, blood coagulation
INFLAMMATORY BOWEL DISEASE, CARCINOMA OF THE STOMACH, CANCER, ULCERATION, HYPERSENSITIVITY
Patients for whom ESD was indicated (following the Japanese gastric/colorectal cancer treatment guidelines and the gastric/colorectal ESD/endoscopic mucosal resection guidelines) (The exclusion criteria were as follows: residual or local recurrent lesions, ulceration of the target lesions, poorly differentiated adenocarcinoma or undifferentiated carcinoma of the stomach or rectum, inflammatory bowel disease, a history of hypersensitivity to peptide preparations or protein preparations, and a performance status grade of 2 or higher based on the clinical evaluation criteria for cancer chemotherapy. Patients who were considered ineligible for the study by a principal investigator or subinvestigators, those who were receiving blood coagulation drugs (hemocoagulase, among others) and antifibrinolytic agents (tranexamic acid and aprotinin preparations, among others), and cases in which oozing was not observed during surgery were excluded.